Advertisement

Hepatitis C Treatment Among Commercially or Medicaid-Insured Individuals, 2014–2018

      Introduction

      The proportion of individuals infected with hepatitis C virus that receive direct-acting antiviral treatment is unclear.

      Methods

      The proportion of commercially or Medicaid-insured patients receiving hepatitis C virus treatment was estimated using administrative claims data obtained from MarketScan and Multi-State Medicaid obtained on January 6, 2020. Validated algorithms derived from standardized procedures and International Classification of Diseases diagnosis codes were used to identify enrollees with chronic hepatitis C; analysis (performed November 30, 2020) was restricted to adults continuously enrolled with prescription drug coverage for >6 months before and after their index hepatitis C viral load test claim date from January 2014 through December 2018. Prescription drug claims using National Drug Codes were used for hepatitis C virus drugs. The proportion of treated patients by demographic and clinical characteristics was described, and associations with treatment were modeled using multivariable-adjusted hazard ratios and 95% CIs by insurance status.

      Results

      Of patients with chronic hepatitis C, 12,090 of 17,562 (69%) with commercial insurance and 8,112 of 27,328 (30%) with Medicaid were treated. Commercially insured patients with opioid use disorder (hazard ratio=0.78, 95% CI=0.72, 0.85), alcohol use disorder (hazard ratio=0.85, 95% CI=0.79, 0.91), severe mental illness (hazard ratio=0.92, 95% CI=0.87, 0.98), chronic kidney disease (hazard ratio=0.75, 95% CI=0.69, 0.82), or HIV infection (hazard ratio=0.74, 95% CI=0.66, 0.82) were less likely to be treated. Medicaid patients with opioid (hazard ratio=0.64, 95% CI=0.61, 0.68) or alcohol use disorders (hazard ratio=0.83, 95% CI=0.79, 0.88) were less likely to be treated.

      Conclusions

      Hepatitis C virus treatment gaps were identified using administrative claims data among patients with commercial and Medicaid insurance.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Hofmeister MG
        • Rosenthal EM
        • Barker LK
        • et al.
        Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016.
        Hepatology. 2019; 69: 1020-1031https://doi.org/10.1002/hep.30297
        • Ryerson AB
        • Schillie S
        • Barker LK
        • Kupronis BA
        • Wester C
        Vital signs: newly reported acute and chronic hepatitis C cases - United States, 2009-2018.
        MMWR Morb Mortal Wkly Rep. 2020; 69: 399-404https://doi.org/10.15585/mmwr.mm6914a2
        • Denniston MM
        • Jiles RB
        • Drobeniuc J
        • et al.
        Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.
        Ann Intern Med. 2014; 160: 293-300https://doi.org/10.7326/M13-1133
        • Ly KN
        • Hughes EM
        • Jiles RB
        • Holmberg SD
        Rising mortality associated with hepatitis C virus in the United States, 2003-2013.
        Clin Infect Dis. 2016; 62: 1287-1288https://doi.org/10.1093/cid/ciw111
      1. American Association for the Study of Liver Disease, Infectious Disease Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org Updated May 26, 2021. Accessed October 28, 2020.

        • WHO
        Combating hepatitis B and C to reach elimination by 2030.
        WHO, Geneva, Switzerland2016 (Published May)
        • Schillie S
        • Wester C
        • Osborne M
        • Wesolowski L
        • Ryerson AB
        CDC recommendations for hepatitis C screening among adults - United States, 2020.
        MMWR Recomm Rep. 2020; 69: 1-17https://doi.org/10.15585/mmwr.rr6902a1
        • Safreed-Harmon K
        • Blach S
        • Aleman S
        • et al.
        The consensus hepatitis C cascade of care: standardized reporting to monitor progress toward elimination.
        Clin Infect Dis. 2019; 69: 2218-2227https://doi.org/10.1093/cid/ciz714
      2. MarketScan research databases. IBM. https://www.ibm.com/products/marketscan-research-databases/databases. Accessed April 29, 2021.

        • Isenhour C
        • Hariri S
        • Vellozzi C
        Monitoring the hepatitis C care cascade using administrative claims data.
        Am J Manag Care. 2018; 24: 232-238
        • National Academies of Sciences, Engineering, and Medicine
        A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report.
        The National Academies Press, Washington, DC2017https://doi.org/10.17226/24731
        • Kramer JR
        • Davila JA
        • Miller ED
        • Richardson P
        • Giordano TP
        • El-Serag HB
        The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases.
        Aliment Pharmacol Ther. 2008; 27: 274-282https://doi.org/10.1111/j.1365-2036.2007.03572.x
        • Niu B
        • Forde KA
        • Goldberg DS
        Coding algorithms for identifying patients with cirrhosis and hepatitis B or C virus using administrative data.
        Pharmacoepidemiol Drug Saf. 2015; 24: 107-111https://doi.org/10.1002/pds.3721
        • Maier MM
        • Ross DB
        • Chartier M
        • Belperio PS
        • Backus LI
        Cascade of care for hepatitis C virus infection within the U.S. Veterans Health Administration.
        Am J Public Health. 2016; 106: 353-358https://doi.org/10.2105/AJPH.2015.302927
        • Holmberg SD
        • Spradling PR
        • Moorman AC
        • Denniston MM
        Hepatitis C in the United States.
        N Engl J Med. 2013; 368: 1859-1861https://doi.org/10.1056/NEJMp1302973
        • Miller LS
        • Millman AJ
        • Lom J
        • et al.
        Defining the hepatitis C cure cascade in an urban health system using the electronic health record [published correction appears in J Viral Hepat. 2021;28(2):449].
        J Viral Hepat. 2020; 27: 13-19https://doi.org/10.1111/jvh.13199
        • Miller LS
        • Rollin F
        • Fluker SA
        • et al.
        High-yield birth-cohort hepatitis C virus screening and linkage to care among underserved African Americans, Atlanta, Georgia, 2012-2013.
        Public Health Rep. 2016; 131: 84-90https://doi.org/10.1177/00333549161310S213
        • Bajis S
        • Dore GJ
        • Hajarizadeh B
        • Cunningham EB
        • Maher L
        • Grebely J
        Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review.
        Int J Drug Policy. 2017; 47: 34-46https://doi.org/10.1016/j.drugpo.2017.07.002
        • Ward JW
        Strategies for expanding access to HBV and HCV testing and care in the United States: the CDC Hepatitis Testing and Linkage to Care Initiative, 2012-2014.
        Public Health Rep. 2016; 131: 1-4https://doi.org/10.1177/00333549161310S201
      3. Viral Hepatitis: funded Partners and programs. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis/policy/fundedpartners.htm. Accessed November 5, 2020.

        • Cope R
        • Glowa T
        • Faulds S
        • McMahon D
        • Prasad R
        Treating hepatitis C in a Ryan White-funded HIV clinic: has the treatment uptake improved in the interferon-free directly active antiviral era?.
        AIDS Patient Care STDs. 2016; 30: 51-55https://doi.org/10.1089/apc.2015.0222
        • Lo Re 3rd, V
        • Gowda C
        • Urick PN
        • et al.
        Disparities in absolute denial of modern hepatitis C therapy by type of insurance.
        Clin Gastroenterol Hepatol. 2016; 14: 1035-1043https://doi.org/10.1016/j.cgh.2016.03.040
        • Canary LA
        • Klevens RM
        • Holmberg SD
        Limited access to new hepatitis C virus treatment under state Medicaid programs.
        Ann Intern Med. 2015; 163: 226-228https://doi.org/10.7326/M15-0320
        • National Viral Hepatitis Roundtable, Center for Health Law and Policy Innovation, Harvard Law School
        Hepatitis C: the state of Medicaid access: 2017 national summary report.
        National Viral Hepatitis Roundtable, Center for Health Law and Policy Innovation, Harvard Law School, Cambridge, MA2017 (Published October 23)
        • Barua S
        • Greenwald R
        • Grebely J
        • Dore GJ
        • Swan T
        • Taylor LE
        Restrictions for Medicaid reimbursement of Sofosbuvir for the treatment of hepatitis C virus infection in the United States.
        Ann Intern Med. 2015; 163: 215-223https://doi.org/10.7326/M15-0406
        • Campbell CA
        • Canary L
        • Smith N
        • Teshale E
        • Ryerson AB
        • Ward JW
        State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs - United States, 2015-2016 [published correction appears in MMWR Morb Mortal Wkly Rep. 2017;66(29):795].
        MMWR Morb Mortal Wkly Rep. 2017; 66: 465-469https://doi.org/10.15585/mmwr.mm6618a2